Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade
Abstract Treatment with immune checkpoint inhibitors has altered the course of malignant melanoma, with approximately half of the patients with advanced disease surviving for more than 5 years after diagnosis. Currently, there are no biomarker methods for predicting outcome from immunotherapy. Here,...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nature Portfolio
2022-12-01
|
| Edice: | npj Precision Oncology |
| On-line přístup: | https://doi.org/10.1038/s41698-022-00330-3 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
